Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
27.07
+0.70 (2.65%)
At close: Aug 1, 2025, 4:00 PM
27.29
+0.22 (0.81%)
After-hours: Aug 1, 2025, 7:59 PM EDT
Summit Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
159
Market Cap
20.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 705.00K | -1.10M | -61.03% |
| Dec 31, 2021 | 1.81M | 949.00K | 110.35% |
| Dec 31, 2020 | 860.00K | 49.46K | 6.10% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
SMMT News
- 18 days ago - SMMT Investors Have Opportunity to Join Summit Therapeutics Inc. Fraud Investigation with the Schall Law Firm - Business Wire
- 4 weeks ago - Summit Therapeutics: AstraZeneca Partnership Could Be A Game-Changer, But Clinical Risks Remain - Seeking Alpha
- 4 weeks ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire
- 2 months ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Summit Therapeutics to Participate in the 46th Annual Goldman Sachs Global Healthcare Conference - Business Wire
- 2 months ago - Summit Therapeutics: Market Overreaction Creates Opportunity - Seeking Alpha
- 2 months ago - Is SMMT Stock A Buy After Its Recent Plunge? - Forbes
- 2 months ago - Summit Therapeutics: Moving Stock To 'Hold' Rating After Phase 3 HARMONi Data Release - Seeking Alpha